Spectral AI (NASDAQ: MDAI) announced that its research partners, RCSI Skin Wounds and Trauma Research Center and RCSI Connolly Hospital, have won the Best Research Project at the 2025 Education Awards for their Diabetic Foot Ulcers project using the DeepView System. The project showcased the integration of real-time multispectral imaging with AI-driven analytics to improve evaluation and treatment strategies for diabetic foot ulcers. The Education Awards, part of the BusinessRiver network connecting over 12,000 senior professionals, recognize excellence in third-level education across Ireland. This achievement validates the clinical value of Spectral AI's DeepView System and generates valuable real-world data as the company prepares for broader market commercialization.
Spectral AI (NASDAQ: MDAI) ha annunciato che i suoi partner di ricerca, il RCSI Skin Wounds and Trauma Research Center e l'RCSI Connolly Hospital, hanno vinto il Premio per il Miglior Progetto di Ricerca agli Education Awards 2025 per il loro progetto sulle ulcere del piede diabetico utilizzando il sistema DeepView. Il progetto ha dimostrato l'integrazione di imaging multispettrale in tempo reale con analisi basate sull'intelligenza artificiale per migliorare la valutazione e le strategie di trattamento delle ulcere del piede diabetico. Gli Education Awards, parte della rete BusinessRiver che collega oltre 12.000 professionisti senior, riconoscono l'eccellenza nell'istruzione terziaria in tutta l'Irlanda. Questo risultato conferma il valore clinico del sistema DeepView di Spectral AI e genera dati reali preziosi mentre l'azienda si prepara a una commercializzazione più ampia sul mercato.
Spectral AI (NASDAQ: MDAI) anunció que sus socios de investigación, el RCSI Skin Wounds and Trauma Research Center y el RCSI Connolly Hospital, ganaron el Mejor Proyecto de Investigación en los Education Awards 2025 por su proyecto sobre Úlceras del Pie Diabético utilizando el sistema DeepView. El proyecto mostró la integración de imágenes multiespectrales en tiempo real con análisis impulsados por IA para mejorar la evaluación y las estrategias de tratamiento de las úlceras del pie diabético. Los Education Awards, parte de la red BusinessRiver que conecta a más de 12,000 profesionales senior, reconocen la excelencia en la educación superior en toda Irlanda. Este logro valida el valor clínico del sistema DeepView de Spectral AI y genera datos valiosos del mundo real mientras la empresa se prepara para una comercialización más amplia en el mercado.
Spectral AI(NASDAQ: MDAI)는 연구 파트너인 RCSI Skin Wounds and Trauma Research Center와 RCSI Connolly Hospital이 2025년 교육상(Education Awards)에서 최우수 연구 프로젝트 상을 수상했다고 발표했습니다. 이 프로젝트는 DeepView 시스템을 활용한 당뇨병성 족부 궤양 연구로, 실시간 다중분광 영상과 AI 기반 분석을 통합하여 당뇨병성 족부 궤양의 평가 및 치료 전략을 개선하는 내용을 선보였습니다. 비즈니스리버(BusinessRiver) 네트워크의 일환인 교육상은 아일랜드 전역의 고등교육 분야 우수성을 인정하는 상으로, 12,000명 이상의 고위 전문가들이 참여하고 있습니다. 이번 성과는 Spectral AI의 DeepView 시스템의 임상적 가치를 입증하며, 회사가 시장 내 광범위한 상업화를 준비하는 데 있어 귀중한 실제 데이터를 생성합니다.
Spectral AI (NASDAQ : MDAI) a annoncé que ses partenaires de recherche, le RCSI Skin Wounds and Trauma Research Center et l'hôpital RCSI Connolly, ont remporté le Meilleur Projet de Recherche lors des Education Awards 2025 pour leur projet sur les ulcères du pied diabétique utilisant le système DeepView. Le projet a démontré l'intégration de l'imagerie multispectrale en temps réel avec des analyses pilotées par l'IA afin d'améliorer l'évaluation et les stratégies de traitement des ulcères du pied diabétique. Les Education Awards, faisant partie du réseau BusinessRiver qui réunit plus de 12 000 professionnels seniors, récompensent l'excellence dans l'enseignement supérieur en Irlande. Cette réussite confirme la valeur clinique du système DeepView de Spectral AI et génère des données précieuses du monde réel alors que l'entreprise se prépare à une commercialisation plus large sur le marché.
Spectral AI (NASDAQ: MDAI) gab bekannt, dass seine Forschungspartner, das RCSI Skin Wounds and Trauma Research Center und das RCSI Connolly Hospital, beim Education Awards 2025 den Besten Forschungsprojektpreis für ihr Projekt zu diabetischen Fußgeschwüren mit dem DeepView-System gewonnen haben. Das Projekt zeigte die Integration von echtzeit-multispektraler Bildgebung mit KI-gestützter Analyse, um die Bewertung und Behandlungsstrategien für diabetische Fußgeschwüre zu verbessern. Die Education Awards, Teil des BusinessRiver-Netzwerks, das über 12.000 leitende Fachkräfte verbindet, würdigen Exzellenz in der tertiären Bildung in ganz Irland. Dieser Erfolg bestätigt den klinischen Wert des DeepView-Systems von Spectral AI und liefert wertvolle reale Daten, während das Unternehmen sich auf eine breitere Markteinführung vorbereitet.
Positive
None.
Negative
None.
DALLAS, May 20, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today announced that its research partners, RCSI Skin Wounds and Trauma (SWaT) Research Center and RCSI Connolly Hospital, have been awarded Best Research Project at the 2025 Education Awards utilizing the DeepView System for their Diabetic Foot Ulcers (DFUs) project.
The Education Awards recognize, encourage and celebrate excellence in third-level education across Ireland, including both state-funded and private institutions. The awards are part of the BusinessRiver network, which connects more than 12,000 senior professionals through more than 30 award programs spanning a range of industries.
“This project highlights the innovative integration of real-time multispectral imaging with AI-driven analytics to guide faster and more effective evaluation and potential treatment strategies for diabetic foot ulcers. In working with our DeepView System, this award celebrates a remarkable cross-disciplinary research effort that brings together clinical, academic, and industry expertise,” said Michael DiMaio, Chairman of the Board. “This project was awarded the Best Research Project as it features an innovative use of AI and imaging for real-time wound assessment, showcasing the cutting-edge technology of the DeepView System in the pursuit of improved patient outcomes.”
“This award-winning research by our partners at RCSI is a significant milestone in validating the clinical value of our DeepView® System,” said Jeremiah Sparks, Chief Commercialization Officer of Spectral AI. “The real-world data generated in Ireland is not only expanding the clinical evidence base for DeepView but also helping shape our strategy for commercialization. These findings position us strongly as we prepare to bring DeepView to broader markets.”
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. The DeepView® System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView® System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView® System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
For Media and Investor Relations, please contact:
David Kugelman Atlanta Capital Partners LLC (866) 692-6847 Toll Free - U.S. & Canada (404) 281-8556 Mobile and WhatsApp Email: dk@atlcp.com
FAQ
What award did Spectral AI's research partners win at the 2025 Education Awards?
Spectral AI's research partners, RCSI SWaT Research Center and RCSI Connolly Hospital, won the Best Research Project award for their Diabetic Foot Ulcers project using the DeepView System.
How does Spectral AI's DeepView System work for diabetic foot ulcers?
The DeepView System combines real-time multispectral imaging with AI-driven analytics to guide faster and more effective evaluation and potential treatment strategies for diabetic foot ulcers.
What is the significance of this award for MDAI stock?
The award validates the clinical value of Spectral AI's DeepView System and provides real-world data that supports the company's commercialization strategy for broader markets.
Who are Spectral AI's research partners in this award-winning project?
The research partners are the RCSI Skin Wounds and Trauma (SWaT) Research Center and RCSI Connolly Hospital in Ireland.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
